Janet Loesberg
Chief Tech/Sci/R&D Officer at BLUEPRINT MEDICINES CORPORATION
Profile
Janet Loesberg is currently the Director at Ambrx, Inc., the Director at All In Together Campaign, Inc., the Independent Director at Ambrx Biopharma Cayman, Inc., the Senior Vice President-Global Medical Affairs at Blueprint Medicines Corp., and the President of The Loesberg Group LLC.
She previously served as the Independent Director at Ambrx Biopharma, Inc. and the VP, Head-Portfolio, Project Management & R&D at Janssen Pharmaceuticals, Inc. Dr. Loesberg holds a doctorate degree from the University of Michigan.
Janet Loesberg active positions
| Companies | Position | Start |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Chief Tech/Sci/R&D Officer | 2020-02-29 |
| AMBRX INC | Director/Board Member | 2022-05-31 |
Ambrx Biopharma, Inc.
 Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Director/Board Member | 2022-06-01 |
| All In Together Campaign, Inc. | Director/Board Member | - |
| The Loesberg Group LLC | President | - |
Former positions of Janet Loesberg
| Companies | Position | End |
|---|---|---|
Janssen Pharmaceuticals, Inc.
 Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Chief Tech/Sci/R&D Officer | 2020-02-29 |
Training of Janet Loesberg
| University of Michigan | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| BLUEPRINT MEDICINES CORPORATION | Health Technology |
| Private companies | 5 |
|---|---|
Janssen Pharmaceuticals, Inc.
Janssen Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Janssen Pharmaceuticals, Inc. develops and markets prescription drugs in various therapeutic areas, including attention deficit hyperactivity disorder, pain management, acid reflux and infectious diseases, women’s health, and mental health (bipolar I disorder and schizophrenia); and neurologic, including Alzheimer’s disease, epilepsy, and migraine prevention and treatment. Its products include Axert, Darzalezx, Invokamet XR, Invokana, Remicade, Reopro, and Risperdal Consta. The company was founded by Paul Janssen in 1953 and is headquartered in Titusville, NJ. | Health Technology |
Ambrx, Inc.
 Ambrx, Inc. Pharmaceuticals: MajorHealth Technology Ambrx, Inc. engages in discovering and developing of protein therapeutics. It offers non-native amino acids through expanded genetic code to both generate novel bio-therapeutics. The company was founded by Richard DiMarchi, Peter G. Schultz, and Troy E. Wilson on April 15, 2003 and is headquartered in La Jolla, CA. | Health Technology |
| All In Together Campaign, Inc. | |
Ambrx Biopharma, Inc.
Ambrx Biopharma, Inc. BiotechnologyHealth Technology Ambrx Biopharma Cayman, Inc. operates as a clinical-stage biologics company. It focuses on discovering and developing a novel class of engineered precision biologics using its proprietary expanded genetic code technology platform that allows it to incorporate, in a site-specific manner, synthetic amino acids that do not exist in nature into proteins within living cells. The company was founded in January 2003 and is headquartered in La Jolla, CA. | Health Technology |
| The Loesberg Group LLC |
- Stock Market
- Insiders
- Janet Loesberg